tetano
Editor, Senior Moderator
Vaccine. 2016 May 4. pii: S0264-410X(16)30237-7. doi: 10.1016/j.vaccine.2016.04.072. [Epub ahead of print]
[h=1]Influenza vaccine effectiveness in Italy: Age, subtype-specific and vaccine type estimates 2014/15 season.[/h] Rizzo C[SUP]1[/SUP], Bella A[SUP]2[/SUP], Alfonsi A[SUP]2[/SUP], Puzelli S[SUP]2[/SUP], Palmieri AP[SUP]2[/SUP], Chironna M[SUP]3[/SUP], Pariani E[SUP]4[/SUP], Piatti A[SUP]5[/SUP], Tiberti D[SUP]6[/SUP], Ghisetti V[SUP]7[/SUP], Rangoni R[SUP]8[/SUP], Colucci ME[SUP]9[/SUP], Affanni P[SUP]9[/SUP], Germinario C[SUP]3[/SUP], Castrucci MR[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The 2014/15 influenza season in Europe was characterised by the circulation of influenza A(H3N2) viruses with an antigenic and genetic mismatch from the vaccine strain A/Texas/50/2012(H3N2) recommended for the Northern hemisphere for the 2014/15 season. Italy, differently from other EU countries where most of the subtyped influenza A viruses were H3N2, experienced a 2014/15 season characterized by an extended circulation of two influenza viruses: A(H1N1)pdm09 and A(H3N2), that both contributed substantially to morbidity. Within the context of the existing National sentinel influenza surveillance system (InfluNet) a test-negative case-control study was established in order to produce vaccine effectiveness (VE) estimates. The point estimates VE were adjusted by age group (<5; 5-15; 15-64; 65+ years), the presence of at least one chronic condition, target group for vaccination and need help for walking or bathing. In Italy, adjusted estimates of the 2014/15 seasonal influenza VE against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza for all age groups were 6.0% (95%CI: -36.5 to 35.2%), 43.6% (95%CI: -3.7 to 69.3%), -84.5% (95%CI: (-190.4 to -17.2%) and 50.7% (95% CI: -2.5 to 76.3%) against any influenza virus, A(H1N1)pdm09, A(H3N2) and B, respectively. These results suggest evidence of good VE against A(H1N1)pdm09 and B viruses in Italy and evidence of lack of VE against A(H3N2) virus due to antigenic and genetic mismatch between circulating A(H3N2) and the respective 2014/15 vaccine strain.
Copyright ? 2016 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Influenza; Test negative case?control studies; Vaccine effectiveness
PMID: 27154392 [PubMed - as supplied by publisher] [h=1].[/h]
[h=1]Influenza vaccine effectiveness in Italy: Age, subtype-specific and vaccine type estimates 2014/15 season.[/h] Rizzo C[SUP]1[/SUP], Bella A[SUP]2[/SUP], Alfonsi A[SUP]2[/SUP], Puzelli S[SUP]2[/SUP], Palmieri AP[SUP]2[/SUP], Chironna M[SUP]3[/SUP], Pariani E[SUP]4[/SUP], Piatti A[SUP]5[/SUP], Tiberti D[SUP]6[/SUP], Ghisetti V[SUP]7[/SUP], Rangoni R[SUP]8[/SUP], Colucci ME[SUP]9[/SUP], Affanni P[SUP]9[/SUP], Germinario C[SUP]3[/SUP], Castrucci MR[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The 2014/15 influenza season in Europe was characterised by the circulation of influenza A(H3N2) viruses with an antigenic and genetic mismatch from the vaccine strain A/Texas/50/2012(H3N2) recommended for the Northern hemisphere for the 2014/15 season. Italy, differently from other EU countries where most of the subtyped influenza A viruses were H3N2, experienced a 2014/15 season characterized by an extended circulation of two influenza viruses: A(H1N1)pdm09 and A(H3N2), that both contributed substantially to morbidity. Within the context of the existing National sentinel influenza surveillance system (InfluNet) a test-negative case-control study was established in order to produce vaccine effectiveness (VE) estimates. The point estimates VE were adjusted by age group (<5; 5-15; 15-64; 65+ years), the presence of at least one chronic condition, target group for vaccination and need help for walking or bathing. In Italy, adjusted estimates of the 2014/15 seasonal influenza VE against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza for all age groups were 6.0% (95%CI: -36.5 to 35.2%), 43.6% (95%CI: -3.7 to 69.3%), -84.5% (95%CI: (-190.4 to -17.2%) and 50.7% (95% CI: -2.5 to 76.3%) against any influenza virus, A(H1N1)pdm09, A(H3N2) and B, respectively. These results suggest evidence of good VE against A(H1N1)pdm09 and B viruses in Italy and evidence of lack of VE against A(H3N2) virus due to antigenic and genetic mismatch between circulating A(H3N2) and the respective 2014/15 vaccine strain.
Copyright ? 2016 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Influenza; Test negative case?control studies; Vaccine effectiveness
PMID: 27154392 [PubMed - as supplied by publisher] [h=1].[/h]